HOME >> MEDICINE >> NEWS
Brookhaven spotlights: News from the March 2003 American Chemical Society Meeting

- Microbeam Radiation Therapy
(Monday, March 24, 9:45 a.m., room 390, as part of a symposium honoring nuclear chemist Demetrios G. Sarantites with the 2003 Glenn T. Seaborg Award)

Despite considerable recent progress in radiation therapy, radiation treatment of brain tumors is often associated with side effects due to damage to normal brain tissue. But scientists working at the National Synchrotron Light Source at Brookhaven Lab are developing a promising radiation therapy technique that is effective in destroying tumors in animal models while sparing normal tissues.

Called microbeam radiation therapy (MRT), this technique, which uses parallel, microscopically thin slices of synchrotron-generated x-rays, preferentially kills tumors in part by acting on blood vessels.

"The way it probably works," says Avraham Dilmanian, MRT's principal investigator and a member of the team that developed the therapy, "is that the endothelial cells, which line the inner walls of blood vessels, survive in the regions between the microbeams, so they can replace the endothelial cells killed by the microbeams. But this repair process somehow fails in the tumor's capillaries because they are very different from those of normal tissues. So, as the tumor's capillaries are destroyed, they cannot feed the tumor anymore, and it eventually dies."

The therapy has not yet been tested in humans and is years away from clinical application, but Dilmanian's results are encouraging. "MRT has proven highly effective in the treatment of certain experimental rat brain tumors, with minimal impact on adjacent normal brain tissue," he says. "Our results support the idea that MRT could offer control of brain cancer with fewer deleterious side effects."

- Two Steps Are Better Than One
(Monday, March 24, 10:50 a.m., room 283)

Brookhaven chemist Hua-Gen Yu has devised a n
'"/>

Contact: Mona Rowe
mrowe@bnl.gov
631-344-5056
DOE/Brookhaven National Laboratory
27-Mar-2003


Page: 1 2 3 4 5

Related medicine news :

1. Brookhaven Lab and BioSET develop a synthetic peptide that enhances the effect of BMP-2
2. Brookhaven lab scientist wins Glenn T. Seaborg Award for Nuclear Chemistry
3. March/April 2005 Annals of Family Medicine tip sheet
4. Chemistry and Flavor of Hispanic Foods one-day symposium, March 15
5. Other highlights in the March 16 JNCI
6. American Thoracic Society Journal news tips for March 2005 (second issue)
7. Annals of Internal Medicine tip sheet for March 15, 2005
8. News briefs from the journal CHEST, March 2005
9. American Thoracic Society Journal news tips for March 2005 (first issue)
10. Other highlights in the March 2 JNCI
11. LA BioMed medical/research briefs March 2005

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/20/2017)... ... August 20, 2017 , ... Are you an adult with gluten intolerance ... you may be interested in participating in a research study that focuses on family ... understand more about the relational aspects of adults who have gluten sensitivities who cohabitate ...
(Date:8/19/2017)... York (PRWEB) , ... August 19, 2017 , ... ... has announced that it is the first organization with pending recognition status from ... Diabetes Prevention Program (“DPP”) via group telehealth classes and live video conferencing. ...
(Date:8/19/2017)... Fla. (PRWEB) , ... August 19, 2017 , ... ... Taufiq Ahmed, M.D., has joined its Orlando location as an interventional pain management ... anesthesiology, a focus on the treatment of migraine headaches, and significant experience in ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... specialized asset-light logistics provider of complex transport solutions for mission-critical and non-discretionary ... Unitrans International Corporation, a division of Roadrunner Transportation Systems, Inc. (NYSE: RRTS). ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Dawn Johnson Insurance ... a new charity drive to generate community support for efforts to educate the local ... and treatments for all types of cancer. , Each day in America, roughly ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 ... from continuing operations Second-quarter ... $110 million Second-quarter 2017 ... Second-quarter 2017 adjusted diluted ... percent to $0.93 Second-quarter ...
(Date:8/7/2017)... 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... ended June 30, 2017.  All comparisons, unless otherwise noted, are ... Second Quarter 2017 Highlights include: ... million, an increase of 3.5% Total prescriptions ... margin of 7.5% versus 7.6% Gross ...
Breaking Medicine Technology:
Cached News: